Trials / Completed
CompletedNCT00584961
BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 553 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the prevalence of Metabolic Syndrome in Spanish population with Bipolar I or II Disorder. To analyse the clinical progress disease in patients with Bipolar I or II Disorder for 12 months using the assessment of the symptoms disease and the progress of metabolic and cardiovascular risk. To analyse the health status, quality of life and functioning/disability of patients.
Detailed description
Consecutive patient sampling. In any investigational site, five consecutive patients with diagnosis of Bipolar Disorder will be enrolled in the study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | non-interventional | non-interventional |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-01-02
- Last updated
- 2021-02-21
Source: ClinicalTrials.gov record NCT00584961. Inclusion in this directory is not an endorsement.